Literature DB >> 11313970

Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.

S H Lee1, M S Shin, H S Kim, H K Lee, W S Park, S Y Kim, J H Lee, S Y Han, J Y Park, R R Oh, C S Kang, K M Kim, J J Jang, S W Nam, J Y Lee, N J Yoo.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-R1 and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL). Because TRAIL/TRAIL receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-R1 and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL. In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-R1 gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-R1 and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-R1 and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R1 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313970     DOI: 10.1038/sj.onc.1204103

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.

Authors:  Ji H Kim; Subash C Gupta; Byoungduck Park; Vivek R Yadav; Bharat B Aggarwal
Journal:  Mol Nutr Food Res       Date:  2011-12-07       Impact factor: 5.914

Review 2.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins.

Authors:  Sahdeo Prasad; Jayaraj Ravindran; Bokyung Sung; Manoj K Pandey; Bharat B Aggarwal
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

4.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

5.  Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway.

Authors:  Ji Hye Kim; Byoungduck Park; Subash C Gupta; Ramaswamy Kannappan; Bokyung Sung; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

6.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Authors:  Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

Review 7.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

8.  Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Phys Biol       Date:  2013-06-04       Impact factor: 2.583

Review 9.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

Review 10.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.